Objectives: This study aimed to determine the effects of vascular endothelial growth factor (VEGF) inhibitors on arterial blood pressure levels by performing ambulatory blood pressure measurement evaluation before and after the treatment.

Patients and methods: In this prospective study, A total of 33 patients (13 males, 20 females; mean age: 58.3±10.6 years; range, 33 to 82 years) were selected among those who applied to the cardiology clinic for cardiac evaluation before VEGF inhibitor treatment between September 2020 and November 2021. Twenty-four-hour ambulatory blood pressure examinations were performed before the treatment, and after four to six weeks of treatment (30 days for oral medications; after the third cycle for bevacizumab), ambulatory blood pressure examinations were repeated.

Results: With the evaluation of mean, ambulatory blood pressure measurement results, an increase was found in systolic and diastolic measurements during the day, night, and over 24 h. A statistically significant increase was observed in mean systolic, mean diastolic, daytime systolic, and daytime diastolic measurements.

Conclusion: Findings demonstrate that VEGF inhibitors increased the mean arterial blood pressure (all day mean, day time, and night time) and both systolic and diastolic pressures regardless of hypertension history. In this context, patients receiving VEGF inhibitor therapy should be more closely followed in their oncological evaluation.